Michelle K. Rhee

Michelle K. Rhee

Auto-generated profile, based on publicly available information

Michelle K. Rhee

Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, Elmhurst, NY

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2023 in Eye & Contact Lens: Science & Clinical Practice
Verified
Journal Article
Open access
MRMichelle K. Rhee
Michelle K. Rhee
EYElizabeth Yeu
Elizabeth Yeu
MBMelissa O.D. Barnett
Melissa O.D. Barnett
CRChristopher J. Rapuano
Christopher J. Rapuano
DDDeepinder K. Dhaliwal
Deepinder K. Dhaliwal
IGIan Gaddie
Ian Gaddie
Demodex blepharitis is a common disease of the eyelid, affecting approximately 25 million Americans. This article reviews what is known about the mechanisms and impact of Demodex blepharitis, risk factors, signs and symptoms, diagnostic techniques, current management options, and emerging treatments. Demodex mites contribute to blepharitis in several ways: direct mechanical damage, as a vector for bacteria, and by inducing hypersensitivity and inflammation. Risk factors for Demodex blepharitis include increasing age, rosacea, and diabetes. The costs, symptom burden, and psychosocial effects of Demodex blepharitis are considerable. The presence of collarettes is pathognomonic for Demodex blepharitis. Redness, dryness, discomfort, foreign body sensation, lash anomalies, and itching are also hallmarks of the disease. Although a number of oral, topical, eyelid hygiene and device-based options have been used clinically and evaluated in studies for the management of Demodex blepharitis, none have been FDA approved to treat the disease. Recent randomized controlled clinical trials suggest that lotilaner ophthalmic solution, 0.25%, is a topical treatment with the potential to eradicate Demodex mites and eliminate collarettes and eyelid redness for an extended period.

1 August 2004 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
MRMichelle K. Rhee
Michelle K. Rhee
RKRegis P. Kowalski
Regis P. Kowalski
EREric G. Romanowski
Eric G. Romanowski
FMFrancis S. Mah
Francis S. Mah
DRDavid C. Ritterband
David C. Ritterband
YGY.JErold Gordon
Y.JErold Gordon

10 June 2022 in Eye & Contact Lens: Science & Clinical Practice
Verified
Journal Article
Open access
MRMichelle K. Rhee
Michelle K. Rhee
DJDeborah S. M.D. Jacobs
Deborah S. M.D. Jacobs
DDDeepinder K. M.D. Dhaliwal
Deepinder K. M.D. Dhaliwal
LSLoretta O.D. Szczotka-Flynn
Loretta O.D. Szczotka-Flynn
CPChristina R. M.D. Prescott
Christina R. M.D. Prescott
BJBennie H. Jeng
Bennie H. Jeng
Contact lenses are a safe and effective method for correction of refractive error and worn by an estimated 45 million Americans. Because of the widespread availability and commercial popularity of contact lenses, it is not well appreciated by the public that contact lenses are U.S. Food and Drug Administration (FDA)–regulated medical devices. Contact lenses are marketed in numerous hard and soft materials that have been improved over decades, worn in daily or extended wear, and replaced in range of schedules from daily to yearly or longer. Lens materials and wear and care regimens have impact on the risks of contact lens–related corneal inflammatory events and microbial keratitis. This article reviews contact lens safety, with specific focus on the correction of refractive error in healthy eyes.

1 March 2022 in Eye & Contact Lens: Science & Clinical Practice
Verified
Journal Article
Closed access
MRMichelle K Rhee
Michelle K Rhee
MKMichelle K.
Michelle K.
Myopia is a global epidemic on the rise, garnering increased attention, particularly in therapeutics and prevention, and the field of myopia control. This study reviews the current management options including contact lenses, spectacles, atropine, and environmental and behavioral modifications. Particular attention is given to the US perspective.